Clinical trial · Interventional
First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study
NCT00537901CI-TRIAL-00020227completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colonic Neoplasms | Colon Neoplasm | ALIAS | 0.90 |
| Rectal Neoplasms | Rectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| First-Line Bevacizumab and Chemotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Effectiveness
- timeFrame
- overall
Secondary outcomes (1)
- measure
- Quality of life
- timeFrame
- overall
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with metastatic cancer of colon or rectum
References
Publications (0)
Data not yet available
No reference posted for this study.